AIM: We designed a study to estimate the economic impact of @entity56501 Surgical Sealant for the prevention of @entity548 in cardiac and vascular surgery. We also explored the potential economic value of @entity56501 as a means of inhibiting the formation of pericardial tissue adhesions. METHODS: A Delphi panel of 6 expert vascular and cardiac surgeons provided the assumptions and estimates needed to develop a decision analysis model to assess the impact of sealant on the costs associated with low- and high-risk forms of cardiac (valve replacement/reconstruction) and vascular ( @entity1028 [ @entity1028 ] repair, femoral bypass grafting) surgery. The primary outcome was incremental cost per @entity1 . RESULTS: For valve repair/replacement surgery, sealant was expected to confer cost-savings in high-risk but not low-risk procedures. Predicted cost savings for high-risk @entity1028 repairs were substantial, but minimal in the overall @entity1028 group. Cost-savings were predicted for sealant use in all femoral-popliteal ePTFE bypass grafts, but in high-risk femoral-femoral ePTFE bypass grafts only. CONCLUSIONS: According to our decision analysis model, routine use of surgical sealant in select subgroups may confer considerable economic benefits to health service budgets. Future research should aim at testing this model in a real-world hospital setting. Assessment of the value of @entity56501 in the prevention of postsurgical adhesions showed that expert surgeons see a need for effective prophylaxis. Further research into the clinical and economic benefit of this intervention is required.

The use of a surgical sealant ( XXXX ) in cardiac and vascular reconstructive surgery: an economic analysis.

@entity1 :: ('9606', 'Species') :: ['patient'] @entity1028 :: ('MESH:D017544', 'Disease') :: ['abdominal aortic aneurysm', 'AAA'] @entity56501 :: ('MESH:C513322', 'Chemical') :: ['CoSeal'] @entity548 :: ('MESH:D006470', 'Disease') :: ['anastomotic bleeding']
@entity56501 :: (MESH:C513322,Chemical) :: ['CoSeal']
